Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuping Li

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
Chest|May 16, 2026
Anti-C5a antibody STSA-1002 for patients with acute respiratory distress syndrome due to viral pneumonia: a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trialYeming Wang, Xiaobo Huang, Zhenshun Cheng, et al.
British Journal of Cancer|September 17, 2019
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective studyYanjun Xu, Zhiyu Huang, Hongyang Lu, et al.
Journal of Thoracic Disease|April 11, 2020
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world studyWen Zhang, Yiping Zhang, Qiong Zhao, et al.
BMC Medicine|February 1, 2022
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trialZhengbo Song, Yuping Li, Shiqing Chen, et al.
Nature Communications|September 28, 2017
Erratum: High performance platinum single atom electrocatalyst for oxygen reduction reactionJing Liu, Menggai Jiao, Lanlu Lu, et al.
Nature Communications|July 25, 2017
High performance platinum single atom electrocatalyst for oxygen reduction reactionJing Liu, Menggai Jiao, Lanlu Lu, et al.
Emerging Microbes & Infections|January 27, 2022
Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in ChinaJieming Qu, Jing Zhang, Yu Chen, et al.
Plos One|May 25, 2012
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosisXiwei Wu, Lihong Weng, Xuejun Li, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
Chest|May 16, 2026
Anti-C5a antibody STSA-1002 for patients with acute respiratory distress syndrome due to viral pneumonia: a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trialYeming Wang, Xiaobo Huang, Zhenshun Cheng, et al.
British Journal of Cancer|September 17, 2019
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective studyYanjun Xu, Zhiyu Huang, Hongyang Lu, et al.
Journal of Thoracic Disease|April 11, 2020
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world studyWen Zhang, Yiping Zhang, Qiong Zhao, et al.
BMC Medicine|February 1, 2022
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trialZhengbo Song, Yuping Li, Shiqing Chen, et al.
Nature Communications|September 28, 2017
Erratum: High performance platinum single atom electrocatalyst for oxygen reduction reactionJing Liu, Menggai Jiao, Lanlu Lu, et al.
Nature Communications|July 25, 2017
High performance platinum single atom electrocatalyst for oxygen reduction reactionJing Liu, Menggai Jiao, Lanlu Lu, et al.
Emerging Microbes & Infections|January 27, 2022
Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in ChinaJieming Qu, Jing Zhang, Yu Chen, et al.
Plos One|May 25, 2012
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosisXiwei Wu, Lihong Weng, Xuejun Li, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Pageof 44